September 2004

Contents

Editorial

• Editorial

Conference reports

• XV International World AIDS Conference, 11-16 July 2004, Bangkok

• Dollars, commerce, politics and prejudice all present obstacles to scaling up access to treatment in resource poor countries

• MTCT programmes in South Africa: nevirapine and the minister

• Urgency of global access to ARV treatment for IV drug users

• Replace myths with evidence–based policies on IV drug use

• Adding Combivir to single dose nevirapine for reduction of MTCT significantly reduces resistance

• Lopinavir/r levels reduced during pregnancy

• Another chance for 3TC in patients with M184V mutation?

• Kaletra monotherapy: small studies and early data

• Lowering dose of d4T can maintain efficacy and reduce side effects

• Three-year renal safety with tenofovir; cystatin may be a useful marker

• Fluconazole increases nevirapine levels and risk of serious hepatotoxicity

• Efavirenz interaction with rifampin may not require dose adjustment in patients with low body weight

• Tipranavir significantly lowers doses of saquinavir, amprenavir and lopinavir/r

• Responses to hepatitis vaccinations: an optimum window for protection?

• HBV vaccine, CD4 count and increasing response with double-dose

• Response to Hepatitis A (HAV) vaccine determined by CD4 count

• Inventive ways to explain HAART and adherence to children

• Isoniazid has early and unexpected benefit in reducing childhood mortality

• Lack of keratin overlaying inner foreskin may explain lower HIV infection rates in circumcised men

Antiretrovirals

• US FDA approves Glaxo and Gilead drug combinations

• Abbott applies for once-daily license for lopinavir/r

• AIDS activists respond to NIH decision on overriding HIV drug patent

Treatment access

• A round-up of news about access to treatments with links to sources

Side effects

• Efficacy of acetyl-L-carnitine for antiretroviral toxic neuropathy

Hepatitis coinfection

• Chiron relaxes patent licences for hepatitis C

Other news

• Activists arrested in Nepal in homophobic atmosphere

Correspondence

• SMART study examines the long term benefit risk of interruptions versus continued use of ART

On the web

• Online treatment journals and newsletters

PDFs

• Volume 5 Number 7/8 August/September 2004 PDF